Abstract
Programed cell death plays a key role in promoting human development and maintaining homeostasis. Ferroptosis is a recently identified pattern of programmed cell death that is closely associated with the onset and progression of neurodegenerative diseases. Ferroptosis is mainly caused by the intracellular accumulation of iron-dependent lipid peroxides. The cysteine/glutamate antibody Solute carrier family 7 member 11 (SLC7A11, also known as xCT) functions to import cysteine for glutathione biosynthesis and antioxidant defense. SLC7A11 has a significant impact on ferroptosis, and inhibition of SLC7A11 expression promotes ferroptosis. Moreover, SLC7A11 is also closely associated with neurodegenerative diseases. In this paper, we summarize the relationship between ferroptosis and neurodegenerative diseases and the role of SLC7A11 during this process. The various regulatory mechanisms of SLC7A11 are also discussed. In conclusion, we are looking forward to a theoretical basis for further understanding the occurrence and development of ferroptosis in SLC7A11 and neurodegenerative diseases, and to seek new clues for the treatment of neurodegenerative diseases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
This is a review article.
References
Albrecht P, Lewerenz J, Dittmer S et al (2010) Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target. CNS Neurol Disord Drug Targetsr 9(3):373–382. https://doi.org/10.2174/187152710791292567
Angelova PR, Choi ML, Berezhnov AV et al (2020) Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation. Cell Death Differr 27(10):2781–2796. https://doi.org/10.1038/s41418-020-0542-z
Asanuma M, Miyazaki I, Diaz-Corrales FJ et al (2010) Neuroprotective effects of zonisamide target astrocyte. Ann Neurolr 67(2):239–249. https://doi.org/10.1002/ana.21885
Ashraf A, Jeandriens J, Parkes HG et al (2020) Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: evidence of ferroptosis. Redox Biolr 32:101494. https://doi.org/10.1016/j.redox.2020.101494
Atanassov BS, Mohan RD, Lan X et al (2016) ATXN7L3 and ENY2 coordinate activity of multiple H2B deubiquitinases important for cellular proliferation and tumor growth. Mol Cellr 62(4):558–571. https://doi.org/10.1016/j.molcel.2016.03.030
Ayton S, Wang Y, Diouf I et al (2020) Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol Psychiatryr 25(11):2932–2941. https://doi.org/10.1038/s41380-019-0375-7
Bannai S (1986) Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J Biol Chemr 261(5):2256–2263
Bermejo P, Martín-Aragón S, Benedí J et al (2008) Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer’s disease from mild cognitive impairment. Free Radic Resr 42(2):162–170. https://doi.org/10.1080/10715760701861373
Berson A, Nativio R, Berger SL et al (2018) Epigenetic regulation in neurodegenerative diseases. Trends Neurosci 41(9):587–598. https://doi.org/10.1016/j.tins.2018.05.005
Caccamo A, Maldonado MA, Majumder S et al (2011) Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem 286(11):8924–8932. https://doi.org/10.1074/jbc.M110.180638
Cao JY, Poddar A, Magtanong L et al (2019) A genome-wide haploid genetic screen identifies regulators of glutathione abundance and ferroptosis sensitivity. Cell Rep 26(6):1544-1556.e1548. https://doi.org/10.1016/j.celrep.2019.01.043
Caricasole A, Copani A, Caruso A et al (2003) The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer’s disease? Trends Pharmacol Sci 24(5):233–238. https://doi.org/10.1016/s0165-6147(03)00100-7
Caterino M, Squillaro T, Montesarchio D et al (2018) Huntingtin protein: a new option for fixing the Huntington’s disease countdown clock. Neuropharmacology 135:126–138. https://doi.org/10.1016/j.neuropharm.2018.03.009
Chatterjee S, Cassel R, Schneider-Anthony A et al (2018) Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator. EMBO Mol Med. https://doi.org/10.15252/emmm.201708587
Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5(3):235–245. https://doi.org/10.1016/s1474-4422(06)70373-8
Chen J, Marks E, Lai B et al (2013) Iron accumulates in Huntington’s disease neurons: protection by deferoxamine. PLoS One 8(10):e77023. https://doi.org/10.1371/journal.pone.0077023
Chen L, Hambright WS, Na R et al (2015) Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J Biol Chem 290(47):28097–28106. https://doi.org/10.1074/jbc.M115.680090
Chen D, Fan Z, Rauh M et al (2017) ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner. Oncogene 36(40):5593–5608. https://doi.org/10.1038/onc.2017.146
Choo YS, Johnson GV, MacDonald M et al (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome C release. Hum Mol Genet 13(14):1407–1420. https://doi.org/10.1093/hmg/ddh162
Chu B, Kon N, Chen D et al (2019) ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol 21(5):579–591. https://doi.org/10.1038/s41556-019-0305-6
Conrad M, Sato H (2012) The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino Acids 42(1):231–246. https://doi.org/10.1007/s00726-011-0867-5
Cotticelli MG, Xia S, Lin D et al (2019) Ferroptosis as a novel therapeutic target for Friedreich’s Ataxia. J Pharmacol Exp Ther 369(1):47–54. https://doi.org/10.1124/jpet.118.252759
Crews L, Spencer B, Desplats P et al (2010) Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 5(2):e9313. https://doi.org/10.1371/journal.pone.0009313
Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39(6):889–909. https://doi.org/10.1016/s0896-6273(03)00568-3
DeGregorio-Rocasolano N, Martí-Sistac O, Gasull T (2019) Deciphering the iron side of stroke: neurodegeneration at the crossroads between iron dyshomeostasis, excitotoxicity, and ferroptosis. Front Neurosci 13:85. https://doi.org/10.3389/fnins.2019.00085
Delaidelli A, Richner M, Jiang L et al (2021) α-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response. Acta Neuropathol Commun 9(1):105. https://doi.org/10.1186/s40478-021-01209-3
Derry PJ, Hegde ML, Jackson GR et al (2020) Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective. Prog Neurobiol 184:101716. https://doi.org/10.1016/j.pneurobio.2019.101716
Devos D, Moreau C, Devedjian JC et al (2014) Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal 21(2):195–210. https://doi.org/10.1089/ars.2013.5593
Dionísio PA, Amaral JD, Rodrigues CMP (2021) Oxidative stress and regulated cell death in Parkinson’s disease. Ageing Res Rev 67:101263. https://doi.org/10.1016/j.arr.2021.101263
Dixon SJ, Lemberg KM, Lamprecht MR et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
Dixon SJ, Patel DN, Welsch M et al (2014) Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3:e02523. https://doi.org/10.7554/eLife.02523
Dixon SJ, Winter GE, Musavi LS et al (2015) Human haploid cell genetics reveals roles for lipid metabolism genes in nonapoptotic cell death. ACS Chem Biol 10(7):1604–1609. https://doi.org/10.1021/acschembio.5b00245
Doll S, Proneth B, Tyurina YY et al (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13(1):91–98. https://doi.org/10.1038/nchembio.2239
Duplan E, Giordano C, Checler F et al (2016) Direct α-synuclein promoter transactivation by the tumor suppressor p53. Mol Neurodegene 11:13. https://doi.org/10.1186/s13024-016-0079-2
Fan Z, Wirth AK, Chen D et al (2017) Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis 6(8):e371. https://doi.org/10.1038/oncsis.2017.65
Farr AC, Xiong MP (2021) Challenges and opportunities of deferoxamine delivery for treatment of Alzheimer’s disease, parkinson’s disease, and intracerebral hemorrhage. Mol Pharm 18(2):593–609. https://doi.org/10.1021/acs.molpharmaceut.0c00474
Feng Z, Jin S, Zupnick A et al (2006) p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25(1):1–7. https://doi.org/10.1038/sj.onc.1209021
Fischer W, Currais A, Liang Z et al (2019) Old age-associated phenotypic screening for Alzheimer’s disease drug candidates identifies sterubin as a potent neuroprotective compound from Yerba santa. Redox Biol 21:101089. https://doi.org/10.1016/j.redox.2018.101089
Flamier A, El Hajjar J, Adjaye J et al (2018) Modeling late-onset sporadic Alzheimer’s disease through BMI1 deficiency. Cell Rep 23(9):2653–2666. https://doi.org/10.1016/j.celrep.2018.04.097
Forcina GC, Dixon SJ (2019) GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics 19(18):e1800311. https://doi.org/10.1002/pmic.201800311
Frappier L, Verrijzer CP (2011) Gene expression control by protein deubiquitinases. Curr Opin Genet Dev 21(2):207–213. https://doi.org/10.1016/j.gde.2011.02.005
Fu D, Wang C, Yu L et al (2021) Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling. Cell Mol Biol Lett 26(1):26. https://doi.org/10.1186/s11658-021-00271-y
Gajowiak A, Styś A, Starzyński RR et al (2016) Misregulation of iron homeostasis in amyotrophic lateral sclerosis. Postepy Hig Med Dosw (Online) 70:709–721. https://doi.org/10.5604/17322693.1208036
Gan B (2019) DUBbing ferroptosis in cancer cells. Cancer Res 79(8):1749–1750. https://doi.org/10.1158/0008-5472.Can-19-0487
Gan L, Vargas MR, Johnson DA et al (2012) Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J Neurosci 32(49):17775–17787. https://doi.org/10.1523/jneurosci.3049-12.2012
Gan W, Dai X, Dai X et al (2020) LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat Cell Biol 22(2):246–256. https://doi.org/10.1038/s41556-020-0463-6
Gao S, Duan C, Gao G et al (2015) Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int J Biochem Cell Biol 64:25–33. https://doi.org/10.1016/j.biocel.2015.03.006
Gao M, Yi J, Zhu J et al (2019) Role of mitochondria in ferroptosis. Mol Cell 73(2):354–363. https://doi.org/10.1016/j.molcel.2018.10.042
Gao J, Liu L, Liu C et al (2020) GLT-1 knockdown inhibits ceftriaxone-mediated improvements on cognitive deficits, and GLT-1 and xCT expression and activity in APP/PS1 AD mice. Front Aging Neurosci 12:580772. https://doi.org/10.3389/fnagi.2020.580772
Gao R, Kalathur RKR, Coto-Llerena M et al (2021a) YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med 13(12):e14351. https://doi.org/10.15252/emmm.202114351
Gao Y, Li J, Wu Q et al (2021b) Tetrahydroxy stilbene glycoside ameliorates Alzheimer’s disease in APP/PS1 mice via glutathione peroxidase related ferroptosis. Int Immunopharmacol 99:108002. https://doi.org/10.1016/j.intimp.2021.108002
Gomez M, Germain D (2019) Cross talk between SOD1 and the mitochondrial UPR in cancer and neurodegeneration. Mol Cell Neurosci 98:12–18. https://doi.org/10.1016/j.mcn.2019.04.003
Griffin RJ, Moloney A, Kelliher M et al (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem 93(1):105–117. https://doi.org/10.1111/j.1471-4159.2004.02949.x
Grolez G, Moreau C, Sablonnière B et al (2015) Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease. BMC Neurol 15:74. https://doi.org/10.1186/s12883-015-0331-3
Gu Y, Albuquerque CP, Braas D et al (2017) mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT. Mol Cell 67(1):128–138. https://doi.org/10.1016/j.molcel.2017.05.030
Guiney SJ, Adlard PA, Bush AI et al (2017) Ferroptosis and cell death mechanisms in Parkinson’s disease. Neurochem Int 104:34–48. https://doi.org/10.1016/j.neuint.2017.01.004
Hambright WS, Fonseca RS, Chen L et al (2017) Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol 12:8–17. https://doi.org/10.1016/j.redox.2017.01.021
Han C, Liu Y, Dai R et al (2020) Ferroptosis and its potential role in human diseases. Front Pharmacol 11:239. https://doi.org/10.3389/fphar.2020.00239
Harvey KF, Zhang X, Thomas DM (2013) The Hippo pathway and human cancer. Nat Rev Cancer 13(4):246–257. https://doi.org/10.1038/nrc3458
Hasegawa M, Takahashi H, Rajabi H et al (2016) Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget 7(11):11756–11769. https://doi.org/10.18632/oncotarget.7598
Henry KW, Wyce A, Lo WS et al (2003) Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev 17(21):2648–2663. https://doi.org/10.1101/gad.1144003
Hirata Y, Yamada C, Ito Y et al (2018) Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22 cells. Neuropharmacology 135:242–252. https://doi.org/10.1016/j.neuropharm.2018.03.015
Hu Y, Chopra V, Chopra R et al (2011) Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci USA 108(41):17141–17146. https://doi.org/10.1073/pnas.1104409108
Huang C, Yang M, Deng J et al (2018) Upregulation and activation of p53 by erastin-induced reactive oxygen species contribute to cytotoxic and cytostatic effects in A549 lung cancer cells. Oncol Rep 40(4):2363–2370. https://doi.org/10.3892/or.2018.6585
Ishimoto T, Nagano O, Yae T et al (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc (-) and thereby promotes tumor growth. Cancer Cell 19(3):387–400. https://doi.org/10.1016/j.ccr.2011.01.038
Jankowsky JL, Fadale DJ, Anderson J et al (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13(2):159–170. https://doi.org/10.1093/hmg/ddh019
Jiang L, Hickman JH, Wang SJ et al (2015a) Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses. Cell Cycle 14(18):2881–2885. https://doi.org/10.1080/15384101.2015.1068479
Jiang L, Kon N, Li T et al (2015b) Ferroptosis as a p53-mediated activity during tumour suppression. Naturer 520(7545):57–62. https://doi.org/10.1038/nature14344
Jimenez-Sanchez M, Licitra F, Underwood BR et al (2017) Huntington’s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a024240
Kagan VE, Mao G, Qu F et al (2017) Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 13(1):81–90. https://doi.org/10.1038/nchembio.2238
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912. https://doi.org/10.1016/s0140-6736(14)61393-3
Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698–712. https://doi.org/10.1038/nrd3505
Karuppagounder SS, Alim I, Khim SJ et al (2016) Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models. Sci Transl Med 8(328):328ra329. https://doi.org/10.1126/scitranslmed.aac6008
Kilberg MS, Shan J, Su N (2009) ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol Metab 20(9):436–443. https://doi.org/10.1016/j.tem.2009.05.008
Kim J, Guan KL (2019) mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol 21(1):63–71. https://doi.org/10.1038/s41556-018-0205-1
Klepac N, Relja M, Klepac R et al (2007) Oxidative stress parameters in plasma of Huntington’s disease patients, asymptomatic Huntington’s disease gene carriers and healthy subjects : a cross-sectional study. J Neurol 254(12):1676–1683. https://doi.org/10.1007/s00415-007-0611-y
Knutson MD (2007) Steap proteins: implications for iron and copper metabolism. Nutr Rev 65(7):335–340. https://doi.org/10.1111/j.1753-4887.2007.tb00311.x
Koppula P, Zhang Y, Zhuang L et al (2018) Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond) 38:12. https://doi.org/10.1186/s40880-018-0288-x
Koppula P, Zhuang L, Gan B (2020) Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. https://doi.org/10.1007/s13238-020-00789-5
Kostandy BB (2012) The role of glutamate in neuronal ischemic injury: the role of spark in fire. Neurol Sci 33(2):223–237. https://doi.org/10.1007/s10072-011-0828-5
Koukoulitsa C, Villalonga-Barber C, Csonka R et al (2016) Biological and computational evaluation of resveratrol inhibitors against Alzheimer’s disease. J Enzyme Inhib Med Chem 31(1):67–77. https://doi.org/10.3109/14756366.2014.1003928
Kraft AD, Johnson DA, Johnson JA (2004) Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24(5):1101–1112. https://doi.org/10.1523/jneurosci.3817-03.2004
Lang X, Green MD, Wang W et al (2019) Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov 9(12):1673–1685. https://doi.org/10.1158/2159-8290.Cd-19-0338
Lewerenz J, Hewett S, Huang Y et al (2013) The cystine/glutamate antiporter system Xc−in health and disease: from molecular mechanisms to novel therapeutic oppor-tunities. Antioxid Redox Signal 18:522–555
Li J, Cao F, Yin HL et al (2020) Ferroptosis: past, present and future. Cell Death Dis 11(2):88. https://doi.org/10.1038/s41419-020-2298-2
Liu T, Jiang L, Tavana O et al (2019) The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res 79(8):1913–1924. https://doi.org/10.1158/0008-5472.Can-18-3037
Maher P (2018) Potentiation of glutathione loss and nerve cell death by the transition metals iron and copper: Implications for age-related neurodegenerative diseases. Free Radic Biol Med 115:92–104. https://doi.org/10.1016/j.freeradbiomed.2017.11.015
Mahoney-Sánchez L, Bouchaoui H, Ayton S et al (2021) Ferroptosis and its potential role in the physiopathology of Parkinson’s disease. Prog Neurobiol 196:101890. https://doi.org/10.1016/j.pneurobio.2020.101890
Mancias JD, Wang X, Gygi SP et al (2014) Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 509(7498):105–109. https://doi.org/10.1038/nature13148
Martin-Bastida A, Ward RJ, Newbould R et al (2017) Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease. Sci Rep 7(1):1398. https://doi.org/10.1038/s41598-017-01402-2
Massie A, Schallie A, Kim SW et al (2011) Dopaminergic neurons of system x (c)−-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. Faseb J 25(4):1359–1369. https://doi.org/10.1096/fj.10-177212
Mi Y, Gao X, Xu H et al (2019) The emerging roles of ferroptosis in Huntington’s disease. Neuromol Med 21(2):110–119. https://doi.org/10.1007/s12017-018-8518-6
Miotto G, Rossetto M, Di Paolo ML et al (2020) Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol 28:101328. https://doi.org/10.1016/j.redox.2019.101328
Mitsuda T, Hayakawa Y, Itoh M et al (2007) ATF4 regulates gamma-secretase activity during amino acid imbalance. Biochem Biophys Res Commun 352(3):722–727. https://doi.org/10.1016/j.bbrc.2006.11.075
Miyazaki I, Murakami S, Torigoe N et al (2016) Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice. J Neurochem 136(1):194–204. https://doi.org/10.1111/jnc.13405
Mondal A, Bose S, Banerjee S et al (2021) Role of γ-secretase inhibitors for the treatment of diverse disease conditions through inhibition of notch signaling pathway. Curr Drug Targets 22(15):1799–1807. https://doi.org/10.2174/1389450122666210515161312
Moreau C, Danel V, Devedjian JC et al (2018) Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? Antioxid Redox Signal 29(8):742–748. https://doi.org/10.1089/ars.2017.7493
Nakamura E, Sato M, Yang H et al (1999) 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer. J Biol Chem 274(5):3009–3016. https://doi.org/10.1074/jbc.274.5.3009
Nopoulos PC (2016) Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci 18(1):91–98. https://doi.org/10.31887/DCNS.2016.18.1/pnopoulos
O’Connor T, Sadleir KR, Maus E et al (2008) Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60(6):988–1009. https://doi.org/10.1016/j.neuron.2008.10.047
Ohno M (2014) Roles of eIF2α kinases in the pathogenesis of Alzheimer’s disease. Front Mol Neurosci 7:22. https://doi.org/10.3389/fnmol.2014.00022
Ohta K, Mizuno A, Ueda M et al (2010) Autophagy impairment stimulates PS1 expression and gamma-secretase activity. Autophagy 6(3):345–352. https://doi.org/10.4161/auto.6.3.11228
Pakos-Zebrucka K, Koryga I, Mnich K et al (2016) The integrated stress response. EMBO Rep 17(10):1374–1395
Paraíso AF, Mendes KL, Santos SH (2013) Brain activation of SIRT1: role in neuropathology. Mol Neurobiol 48(3):681–689. https://doi.org/10.1007/s12035-013-8459-x
Powers KM, Smith-Weller T, Franklin GM et al (2009) Dietary fats, cholesterol and iron as risk factors for Parkinson’s disease. Parkinsonism Relat Disord 15(1):47–52. https://doi.org/10.1016/j.parkreldis.2008.03.002
Qi X, Davis B, Chiang YH et al (2016) Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson’s disease model. J Neurochem 138(5):746–757. https://doi.org/10.1111/jnc.13706
Qin S, Colin C, Hinners I et al (2006) System Xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1–40. J Neurosci 26(12):3345–3356. https://doi.org/10.1523/jneurosci.5186-05.2006
Rao SS, Portbury SD, Lago L et al (2020) The iron chelator deferiprone improves the phenotype in a mouse model of tauopathy. J Alzheimers Dis 77(2):753–771. https://doi.org/10.3233/jad-200551
Raven EP, Lu PH, Tishler TA et al (2013) Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer’s disease detected in vivo with magnetic resonance imaging. J Alzheimers Dis 37(1):127–136. https://doi.org/10.3233/jad-130209
Riederer P, Monoranu C, Strobel S et al (2021) Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease. J Neural Transm (Vienna) 128(10):1577–1598. https://doi.org/10.1007/s00702-021-02414-z
Rojo de la Vega M, Chapman E, Zhang DD (2018) NRF2 and the hallmarks of cancer. Cancer Cell 34(1):21–43. https://doi.org/10.1016/j.ccell.2018.03.022
Rosas HD, Chen YI, Doros G et al (2012) Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol 69(7):887–893. https://doi.org/10.1001/archneurol.2011.2945
Saint-Germain E, Mignacca L, Vernier M et al (2017) SOCS1 regulates senescence and ferroptosis by modulating the expression of p53 target genes. Aging (Albany NY) 9(10):2137–2162. https://doi.org/10.18632/aging.101306
Sarkar S, Rubinsztein DC (2008) Small molecule enhancers of autophagy for neurodegenerative diseases. Mol Biosyst 4(9):895–901. https://doi.org/10.1039/b804606a
Sato H, Tamba M, Ishii T et al (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 274(17):11455–11458. https://doi.org/10.1074/jbc.274.17.11455
Sato H, Nomura S, Maebara K et al (2004) Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation. Biochem Biophys Res Commun 325(1):109–116. https://doi.org/10.1016/j.bbrc.2004.10.009
Savaskan NE, Heckel A, Hahnen E et al (2008) Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 14(6):629–632. https://doi.org/10.1038/nm1772
Scheuermann JC, de Ayala Alonso AG, Oktaba K et al (2010) Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature 465(7295):243–247. https://doi.org/10.1038/nature08966
Schneider RB, Iourinets J, Richard IH (2017) Parkinson’s disease psychosis: presentation, diagnosis and management. Neurodegener Dis Manag 7(6):365–376. https://doi.org/10.2217/nmt-2017-0028
Sekhar RV, Patel SG, Guthikonda AP et al (2011) Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. Am J Clin Nutr 94(3):847–853. https://doi.org/10.3945/ajcn.110.003483
Sherman LS, Matsumoto S, Su W et al (2015) Hyaluronan synthesis, catabolism, and signaling in neurodegenerative diseases. Int J Cell Biol 2015:368584. https://doi.org/10.1155/2015/368584
Shi L, Huang C, Luo Q et al (2020) Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson’s disease through AKT/mTOR pathway. Aging (Albany NY) 12(10):9515–9533. https://doi.org/10.18632/aging.103225
Shih AY, Johnson DA, Wong G et al (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23(8):3394–3406. https://doi.org/10.1523/jneurosci.23-08-03394.2003
Skouta R, Dixon SJ, Wang J et al (2014) Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J Am Chem Soc 136(12):4551–4556. https://doi.org/10.1021/ja411006a
Song LM, Xiao ZX, Zhang N et al (2021) Apoferritin improves motor deficits in MPTP-treated mice by regulating brain iron metabolism and ferroptosis. iScience 24(5):102431. https://doi.org/10.1016/j.isci.2021.102431
Spasić S, Nikolić-Kokić A, Miletić S et al (2020) Edaravone may prevent ferroptosis in ALS. Curr Drug Targets 21(8):776–780. https://doi.org/10.2174/1389450121666200220123305
Stefanis L (2012) α-synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 2(2):a009399. https://doi.org/10.1101/cshperspect.a009399
Steffan JS, Kazantsev A, Spasic-Boskovic O et al (2000) The Huntington’s disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A 97(12):6763–6768. https://doi.org/10.1073/pnas.100110097
Stockwell BR, Jiang X (2020) The chemistry and biology of ferroptosis. Cell Chem Biol 27(4):365–375. https://doi.org/10.1016/j.chembiol.2020.03.013
Stockwell BR, Friedmann Angeli JP, Bayir H et al (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171:273–285. https://doi.org/10.1016/j.cell.2017.09.021
Strassnig M, Ganguli M (2005) About a peculiar disease of the cerebral cortex: Alzheimer’s original case revisited. Psychiatry (Edgmont) 2(9):30–33
Straub IR, Weraarpachai W, Shoubridge EA (2021) Multi-OMICS study of a CHCHD10 variant causing ALS demonstrates metabolic rewiring and activation of endoplasmic reticulum and mitochondrial unfolded protein responses. Hum Mol Genet 30(8):687–705. https://doi.org/10.1093/hmg/ddab078
Strosznajder RP, Jesko H, Banasik M et al (2005) Effects of p53 inhibitor on survival and death of cells subjected to oxidative stress. J Physiol Pharmacol 56(Suppl 4):215–221
Suina K, Tsuchihashi K, Yamasaki J et al (2018) Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling. Cancer Sci 109(12):3874–3882. https://doi.org/10.1111/cas.13826
Sun X, Ou Z, Chen R et al (2016) Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63(1):173–184. https://doi.org/10.1002/hep.28251
Sun Y, He L, Wang T et al (2020) Activation of p62-Keap1-Nrf2 pathway protects 6-hydroxydopamine-induced ferroptosis in dopaminergic cells. Mol Neurobiol 57(11):4628–4641. https://doi.org/10.1007/s12035-020-02049-3
Sykiotis GP, Bohmann D (2010) Stress-activated cap’n’collar transcription factors in aging and human disease. Sci Signal 3(112):re3. https://doi.org/10.1126/scisignal.3112re3
Takano T, Lin JH, Arcuino G et al (2001) Glutamate release promotes growth of malignant gliomas. Nat Med 7(9):1010–1015. https://doi.org/10.1038/nm0901-1010
Tamarit J, Obis È, Ros J (2016) Oxidative stress and altered lipid metabolism in Friedreich ataxia. Free Radic Biol Med 100:138–146. https://doi.org/10.1016/j.freeradbiomed.2016.06.007
Tang D, Kroemer G (2020) Ferroptosis. Curr Biol 30(21):R1292-r1297
Tao Y, Wang Y, Rogers JT et al (2014) Perturbed iron distribution in Alzheimer’s disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. J Alzheimers Dis 42(2):679–690. https://doi.org/10.3233/jad-140396
Tian Y, Lu J, Hao X et al (2020) FTH1 inhibits ferroptosis through ferritinophagy in the 6-OHDA model of Parkinson’s disease. Neurotherapeutics 17(4):1796–1812. https://doi.org/10.1007/s13311-020-00929-z
Tsuchihashi K, Okazaki S, Ohmura M et al (2016) The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc (-). Cancer Res 76(10):2954–2963. https://doi.org/10.1158/0008-5472.Can-15-2121
Turchi R, Tortolici F, Guidobaldi G et al (2020) Frataxin deficiency induces lipid accumulation and affects thermogenesis in brown adipose tissue. Cell Death Dis 11(1):51. https://doi.org/10.1038/s41419-020-2253-2
Turnquist C, Horikawa I, Foran E et al (2016) p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Cell Death Differ 23(9):1515–1528. https://doi.org/10.1038/cdd.2016.37
Tysnes OB, Storstein A (2017) Epidemiology of Parkinson’s disease. J Neural Transm (Vienna) 124(8):901–905. https://doi.org/10.1007/s00702-017-1686-y
Ursini F, Maiorino M (2020) Lipid peroxidation and ferroptosis: the role of GSH and GPx4. Free Radic Biol Med 152:175–185. https://doi.org/10.1016/j.freeradbiomed.2020.02.027
Van Do B, Gouel F, Jonneaux A et al (2016) Ferroptosis, a newly characterized form of cell death in Parkinson’s disease that is regulated by PKC. Neurobiol Dis 94:169–178. https://doi.org/10.1016/j.nbd.2016.05.011
van Muiswinkel FL, de Vos RA, Bol JG et al (2004) Expression of NAD (P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging 25(9):1253–1262. https://doi.org/10.1016/j.neurobiolaging.2003.12.010
Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137(3):413–431. https://doi.org/10.1016/j.cell.2009.04.037
Walker FO (2007) Huntington’s disease. Lancet 369(9557):218–228. https://doi.org/10.1016/s0140-6736(07)60111-1
Walker C, Herranz-Martin S, Karyka E et al (2017) C9orf72 expansion disrupts ATM-mediated chromosomal break repair. Nat Neurosci 20(9):1225–1235. https://doi.org/10.1038/nn.4604
Wang H, Wang L, Erdjument-Bromage H et al (2004) Role of histone H2A ubiquitination in polycomb silencing. Nature 431(7010):873–878. https://doi.org/10.1038/nature02985
Wang Y, Yang L, Zhang X et al (2019) Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep 20(7):e47563. https://doi.org/10.15252/embr.201847563
Wang T, Tomas D, Perera ND et al (2022a) Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis. Cell Death Differ 29(6):1187–1198. https://doi.org/10.1038/s41418-021-00910-z
Wang ZL, Yuan L, Li W et al (2022b) Ferroptosis in Parkinson’s disease: glia-neuron crosstalk. Trends Mol Med 28(4):258–269. https://doi.org/10.1016/j.molmed.2022.02.003
Wosik K, Antel J, Kuhlmann T et al (2003) Oligodendrocyte injury in multiple sclerosis: a role for p53. J Neurochem 85(3):635–644. https://doi.org/10.1046/j.1471-4159.2003.01674.x
Wu SF, Zhu ZF, Kong Y et al (2014) Assessment of cerebral iron content in patients with Parkinson’s disease by the susceptibility-weighted MRI. Eur Rev Med Pharmacol Sci 18(18):2605–2608
Wyttenbach A, Sauvageot O, Carmichael J et al (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 11(9):1137–1151. https://doi.org/10.1093/hmg/11.9.1137
Xie Y, Hou W, Song X et al (2016) Ferroptosis: process and function. Cell Death Differ 23(3):369–379. https://doi.org/10.1038/cdd.2015.158
Xu Y, Zhang Y, Zhang JH et al (2020) Astrocyte hepcidin ameliorates neuronal loss through attenuating brain iron deposition and oxidative stress in APP/PS1 mice. Free Radic Biol Med 158:84–95. https://doi.org/10.1016/j.freeradbiomed.2020.07.012
Yagami T, Yamamoto Y, Koma H (2019) Pathophysiological roles of intracellular proteases in neuronal development and neurological diseases. Mol Neurobiol 56(5):3090–3112. https://doi.org/10.1007/s12035-018-1277-4
Yamaguchi I, Yoshimura SH, Katoh H (2020) High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11). J Biol Chem 295(20):6936–6945. https://doi.org/10.1074/jbc.RA119.012213
Yamamoto M, Teramoto K, Katoh H (2021) Epidermal growth factor promotes glioblastoma cell death under glucose deprivation via upregulation of xCT (SLC7A11). Cell Signal 78:109874. https://doi.org/10.1016/j.cellsig.2020.109874
Yang WS, Stockwell BR (2008) Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 15(3):234–245. https://doi.org/10.1016/j.chembiol.2008.02.010
Yang WS, SriRamaratnam R, Welsch ME et al (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156(1–2):317–331. https://doi.org/10.1016/j.cell.2013.12.010
Yang WS, Kim KJ, Gaschler MM et al (2016) Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc Natl Acad Sci USA 113(34):E4966-4975. https://doi.org/10.1073/pnas.1603244113
Yang WH, Ding CC, Sun T et al (2019) The hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma. Cell Rep 28(10):2501–2508. https://doi.org/10.1016/j.celrep.2019.07.107
Ye P, Mimura J, Okada T et al (2014) Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol 34(18):3421–3434. https://doi.org/10.1128/mcb.00221-14
Ye J, Jiang X, Dong Z et al (2019) Low-concentration PTX and RSL3 inhibits tumor cell growth synergistically by inducing ferroptosis in mutant p53 hypopharyngeal squamous carcinoma. Cancer Manag Res 11:9783–9792. https://doi.org/10.2147/cmar.S217944
Ye CL, Du Y, Yu X et al (2022) STEAP3 affects ferroptosis and progression of renal cell carcinoma through the p53/xCT pathway. Technol Cancer Res Treat 21:15330338221078728. https://doi.org/10.1177/15330338221078728
Yehuda S, Rabinovitz S, Carasso RL et al (2002) The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23(5):843–853. https://doi.org/10.1016/s0197-4580(02)00074-x
Yu W, Liu W, Xie D et al (2022) High level of uric acid promotes atherosclerosis by targeting NRF2-mediated autophagy dysfunction and ferroptosis. Oxid Med Cell Longev 2022:9304383. https://doi.org/10.1155/2022/9304383
Yuan H, Li X, Zhang X et al (2016) Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun 478(3):1338–1343. https://doi.org/10.1016/j.bbrc.2016.08.124
Yuan F, Sun Q, Zhang S et al (2022) The dual role of p62 in ferroptosis of glioblastoma according to p53 status. Cell Biosci 12(1):20. https://doi.org/10.1186/s13578-022-00764-z
Zhang Y, Shi J, Liu X et al (2018) BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20(10):1181–1192. https://doi.org/10.1038/s41556-018-0178-0
Zhang Y, Tan H, Daniels JD et al (2019) Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem Biol 26(5):623–633. https://doi.org/10.1016/j.chembiol.2019.01.008
Zhang L, Liu W, Liu F et al (2020a) IMCA induces ferroptosis mediated by SLC7A11 through the AMPK/mTOR pathway in colorectal cancer. Oxid Med Cell Longev 2020:1675613. https://doi.org/10.1155/2020/1675613
Zhang P, Chen L, Zhao Q et al (2020b) Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in Parkinson’s disease. Free Radic Biol Med 152:227–234. https://doi.org/10.1016/j.freeradbiomed.2020.03.015
Zhang Y, Fan D, Liu X et al (2020c) hTBK1-c. 978T>A mutation promotes the ferroptosis in NSC-34 cells via mediation of KEAP1/NRF2/p62 signaling. Am J Transl Res 12(11):7386–7394
Zhang RF, Zeng M, Lv N et al (2023) Ferroptosis in neurodegenerative diseases: inhibitors as promising candidate mitigators. Eur Rev Med Pharmacol Sci 27(1):46–65. https://doi.org/10.26355/eurrev_202301_30852
Funding
This work was supported by National Natural Science Foundation of China (No. 81502779), and Natural Science Foundation of Liaoning province, China (No. QN2019030).
Author information
Authors and Affiliations
Contributions
All authors contributed to the conception and preparation of the manuscript. The manuscript was written by CW and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interest
The authors declare no conflicts of interest.
Consent to Participate
Not applicable. There is not any patient in this research study.
Consent for Publication
Not applicable. There is not any patient in this research study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wang, C., Liu, H., Xu, S. et al. Ferroptosis and Neurodegenerative Diseases: Insights into the Regulatory Roles of SLC7A11. Cell Mol Neurobiol 43, 2627–2642 (2023). https://doi.org/10.1007/s10571-023-01343-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-023-01343-7